Close
Achema middle east
swop processing & packaging

Synthon opens new GMP antibody-drug conjugate production facility in Nijmegen

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Synthon Biopharmaceuticals has opened a GMP antibody-drug conjugate (ADC) production facility in Nijmegen.

The Nijmegen facility will produce ADCs, which combine specific anti-cancer antibody or antibody fragment to an anti-cancer therapeutic, required for Phase III trials and early launches.

Company has also reported positive preclinical results with its HER2-ADC that induced complete tumor remission when dosed alone in xenograft studies.

Toxicity experiments demonstrated improved therapeutic index and a considerable safety profile of HER2-ADC.

Synthon Biopharmaceuticals chief scientific officer Dr. Marco Timmers said the HER2-binding antibody trastuzumab is incorporated into the company’s first ADC program.

“The primary objective is to develop a broad therapeutic spectrum by targeting tumors that over-express HER2, such as metastatic breast cancer and non-small-cell lung cancer,” Dr. Timmers added.

“As a result of our unique linker-drug technology, this ADC program is delivering on its promise and giving us exciting preclinical results with the opportunity to become a Best-in-Class therapy.”

The drug candidate that will be produced in the newly opened GMP facility is expected to enter into clinical trials in 2014.

Latest stories

Related stories

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »